The "Biodefense - A Global Market Overview" report has been added to ResearchAndMarkets.com's offering.
The global Biodefense market is estimated at US$18.2 billion in 2024 and is anticipated to register a CAGR of 8.6% during the 2024-2030 analysis period and stand at a projected US$29.9 billion by 2030.
Biodefense aims to reduce the impact of biological agents and ensure readiness for potential biological emergencies. This requires collaboration among bioscience labs, hospitals, customs, and public health sectors to prevent the use of dangerous pathogens and toxins.
The Biodefense market is driven by technological advancements, rising global health hazards, and substantial government investments. Key drivers include the rapid development of next-generation vaccines and treatments; with artificial intelligence (AI) and machine learning (ML) enhancing early detection and response systems; advances in biodetection technology and point-of-care diagnostics improve outbreak response and early warning capabilities; biosecurity measures are strengthening research facilities and high-risk sectors to prevent pathogen spread; collaborative efforts between governments, academia, and businesses accelerate R&D and technology transfer; and increased government funding, prompted by the threats of bioterrorism and pandemics, fuels market expansion. The COVID-19 pandemic has heightened awareness of healthcare vulnerabilities, driving a focus on bio-surveillance, vaccine development, and emergency response mechanisms. Climate change and global travel increase zoonotic disease risks, further fueling market growth.
Biodefense Market Analysis by Product Type
The anthrax segment leads the market, holding a notable share of 27.8% in 2024. This is attributed to its significant public health impact and ease of dispersion. Anthrax, caused by the Bacillus anthracis bacterium, poses a major bioterrorism threat due to its spore form, which can endure lengthy periods in the environment and spread easily. This segment sees substantial investments in vaccines and countermeasures, driven by past bioterrorism events and ongoing concerns.
On the other hand, the ''Other Products'' segment, which includes diseases such as Influenza, Viral Hemorrhagic Fevers, Ebola, Zika, and others, is expected to grow the fastest with a CAGR of 10.5% from 2024 to 2030. This rapid growth is propelled by the recent rise in infections and the development of new vaccines and treatments for diseases like Zika, Ebola, and Nipah as companies strive to tackle these emerging threats.
Biodefense Market Analysis by Application
The Military segment is projected to hold the largest market share at 64.5% in 2024, driven by substantial government investment in advanced technologies, research, and medical countermeasures to protect national security. The high perceived risk of biological threats and the strategic importance of military preparedness drive extensive funding and development efforts, ensuring robust defenses against potential bioterrorism and biological attacks.
Conversely, the Civilian segment is expected to grow rapidly with a CAGR of 9.1% from 2024 to 2030, due to rising biological threats from terrorist organizations. This growth reflects heightened government efforts and research focused on protecting civilians from potential biological attacks and emerging viruses.
Biodefense Market Analysis by End-User
The hospitals and clinics segment dominates the biodefense market with a 47.1% share in 2024 and is projected to record the fastest CAGR of 9.2% from 2024-2030. This is due to their critical role in managing and treating biological attacks, requiring advanced infrastructure, protective equipment, and diagnostic tools.
Their capacity to handle mass casualties and enhance biodefense preparedness drives their dominant market position. The 'Other End Users' segment, which includes research organizations, biotechnology firms, and government agencies, is experiencing significant market growth driven by increased investment in biodefense research and development, leading to robust performance.
Biodefense Regional Market Analysis
In 2024, North America, led by the U.S., dominated the biodefense market with a 46% share due to significant government investment, robust R&D capabilities, and a strong emphasis on national security. The U.S. government's initiatives, such as the BioShield Act, and the presence of major industry players have bolstered this position.
Conversely, the Asia Pacific region is poised to grow rapidly, with a forecast CAGR of 10.5% from 2024-2030, driven by increased R&D investments and rising biothreat incidents. Countries like China, India, Japan, and South Korea are enhancing biodefense capabilities and investing heavily in public health preparedness, making the Asia Pacific the fastest-growing market segment.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 255 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value (USD) in 2024 | $18.2 Billion |
| Forecasted Market Value (USD) by 2030 | $29.9 Billion |
| Compound Annual Growth Rate | 8.6% |
| Regions Covered | Global |
Key Metrics
- Historical Period: 2021-2023
- Base Year: 2023
- Forecast Period: 2024-2030
- Units: Value market in US$
- Companies Mentioned: 15+
Biodefense Key Global Players
- Alnylam Pharmaceuticals Inc
- Altimmune Inc
- Bavarian Nordic
- Dynavax Technologies Corporation
- Dynport Vaccine Company
- Elusys Therapeutics
- Emergent Biosolutions
- GlaxoSmithKline (UK)
- Ichor Medical Systems
- Ology Bioservices
- Sanofi
- SIGA Technologies
- Soligenix
- Statera BioPharma, Inc.
- Xoma Corporation
Biodefense Market by Geographic Region
- North America (The United States, Canada, and Mexico)
- Europe (Germany, France, The United Kingdom, Spain, Italy, and Rest of Europe)
- Asia-Pacific (Japan, China, India, South Korea, and Rest of Asia-Pacific)
- South America (Brazil, Argentina, and Rest of South America)
- Rest of World
Biodefense Market by Product
- Anthrax
- Smallpox
- Botulism
- Radiation/Nuclear
- Others (Including Influenza, Plague, Cholera, Food Poisoning, Viral Hemorrhagic Fevers, Brucellosis, Glanders, Melioidosis, Tularemia, Viral Encephalitis, Ebola Virus, Zica Virus, Nipah Virus, and Hantavirus)
Biodefense Market by Application
- Military
- Civilian
Biodefense Market by End User
- Hospitals and Clinics
- Ambulatory Care Centers
- Other End Users (Including Research Organizations, Pharmaceutical and Biopharmaceutical Companies, Government Agencies, and Emergency Responders)
For more information about this report visit https://www.researchandmarkets.com/r/dqnq2y
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241122002743/en/
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
